Biotech Behind Oxford’s Coronavirus Vaccine Welcomes AZ’s Big Pharma 'Muscle'

Vaccitech Hails Partner's ‘Aggressive’ Trial Design

 
• By Andrew McConaghie
Vaccitech
Spun out in 2016, Vaccitech has co-developed with Oxford the adenovirus platform used in the COVID-19 vaccine candidate

More from Business

More from Scrip